Immunosuppression enhances oncolytic adenovirus replication and antitumor efficacy in the Syrian Hamster model

Molecular Therapy

Volumn 16, Issue 10, 2008, Pages 1665-1673

  Thomas, Maria A ^a   Spencer, Jacqueline F ^a   Toth, Karoly ^a   Sagartz, John E ^a   Phillips, Nancy J ^a   Wold, William S M ^a  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; ONCOLYTIC ADENOVIRUS; UNCLASSIFIED DRUG; VRX 007;

ANEMIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DISEASE MODEL; DRUG POTENTIATION; DRUG TUMOR LEVEL; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOCOMPETENCE; IMMUNOSUPPRESSIVE TREATMENT; LIVER CELL CARCINOMA; MONOTHERAPY; NONHUMAN; ONCOLYTIC VIROTHERAPY; SYRIAN HAMSTER; TREATMENT OUTCOME; TUMOR GROWTH; TUMOR VOLUME; VIRUS REPLICATION;

ADENOVIRIDAE; ANIMALIA; MESOCRICETUS AURATUS;

EID: 54749109597     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2008.162     Document Type: Article

References (43)

1. Freytag, SO, Stricker, H, Movsas, B and Kim, JH (2007). Prostate cancer gene therapy clinical trials. Mol Ther 15: 1042-1052.
2. Lichtenstein, DL and Wold, WSM (2004). Experimental infections of humans with wild-type adenoviruses and with replication-competent adenovirus vectors: Replication, safety, and transmission. Cancer Gene Ther 11: 819-829.
3. Lin, E and Nemunaitis, J (2004). Oncolytic viral therapies. Cancer Gene Ther 11: 643-664.
4. Thomas, MA, Spencer, JF, La Regina, MC, Dhar, D, Tollefson, AE, Toth, K et al. (2006). Syrian hamster as a permissive immunocompetent animal model for the study of oncolyfic adenovirus vectors. Cancer Res 66: 1270-1276.
5. Toth, K, Djeha, H, Ying, BL, Tollefson, AE, Kuppuswamy, M, Doronin, K et al. (2004). An oncolytic adenovirus vector combining enhanced cell-to-cell spreading, mediated by the ADP cytolytic protein, with selective replication in cancer cells with deregulated Wnt signaling. Cancer Res 64: 3638-3644.
6. Relph, KL, Harrington, KJ and Pandha, H (2005). Adenoviral strategies for the gene therapy of cancer. Semin Oncol 32: 573-582.
7. Youn LS, Searle, PF, Onion, D and Mautner, V (2006). Viral gene therapy strategies: From basic science to clinical application. J Pathol 208: 299-318.
8. Thorne, SH, Hermiston, T and Kim, D (2005). Oncolytic virotherapy: approaches to tumor targeting and enhancing antitumor effects. Semin Oncol 32: 537-548.
9. Jiang, H, McCormick, F, Lang, FF, Gomez-Manzano, C and Fueyo, J (2006). Oncolytic adenoviruses as antiglioma agents. Expert Rev Anticancer Ther 6: 697-708.
10. Assouline, S, Sylvestre, MP, Carriere, P, Shustik, C and Laneuville, P (2006). Comparison of peripheral blood progenitor cell yield from standard chemotherapy used in the treatment of lymphoid malignancies and high-dose cyclophosphamide: A retrospective review of 141 patients. Transfusion (Paris) 46: 174-179.
11. Fehr, T and Sykes, M (2004). Tolerance induction in clinical transplantation. Transpl Immunol 13: 117-130.
12. Ferry, C and Socie, G (2003). Busulfan-cyclophosphamide versus total body irradiation-cyclophosphamide as preparative regimen before allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia: What have we learned? Exp Hematol 31: 1182-1186.
13. Smith, SM (2006). Reduced-intensity transplantation for lymphoma. Curr Treat Options Oncol 7: 295-305.
14. Orlando, L, Cardillo, A, Rocca, A, Balduzzi, A, Ghisini, R, Peruzzotti, G et al. (2006). Prolonged clinical benefit with metronomic chemotherapy in patients with metastatic breast cancer. Anticancer Drugs 17: 961-967.
15. Press, OW, Unger, JM, Braziel, RM, Maloney, DG, Miller, TP, Leblanc, M et al. (2006). Phase II trial of CHOP chemotherapy followed by tositumomab/iodine 1-131 tositumomab for previously untreated follicular non-Hodgkin's lymphoma: Five-year follow-up of Southwest Oncology Group Protocol S9911. J Clin Oncol 24: 4143-4149.
16. Tada, K, Ito, Y, Takahashi, S, Iijima, K, Miyagi, Y, Nishimura, S et al. (2006). Tolerability and safety of classic cyclophosphamide, methotrexate, and Fluorouracil treatment in Japanese patients with early breast cancer. Breast Cancer 13: 279-283.
17. de Jonge, ME, Huitema, AD, Rodenhuis, S and Beijnen, JH (2005). Clinical pharmacokinetics of cyclophosphamide. Clin Pharmacokinet 44: 1135-1164.
18. Parsons, PG, Lean, J, Kable, EP, Favier, D, Khoo, SK, Hurst, T et al (1990). Relationships between resistance to cross-linking agents and glutathione metabolism, aldehyde dehydrogenase isozymes and adenovirus replication in human tumour cell lines. Biochem Pharmacol 40 2641-2649.
19. Bouvet, M, Fang, B, Ekmekcioglu, S, Ji, L, Bucana, CD, Hamada, K et al. (1998). Suppression of the immune response to an adenovirus vector and enhancement of intratumoral transgene expression by low-dose etoposide. Gene Ther 5: 189-195.
20. Jooss, K, Yang, Y and Wilson, IM (1996). Cyclophosphamide diminishes inflammation and prolongs transgene expression following delivery of adenoviral vectors to mouse liver and lung. Hum Gene Ther 7: 1555-1566.
21. Smith, TA, White, BD, Gardner, JM, Kaleko, M and McClelland, A (1996). Transient immunosuppression permits successful repetitive intravenous administration of an adenovirus vector. Gene Ther 3: 496-502.
22. Di Paolo, NC, Tuve, S, Ni, S, Hellstrom, KE, Hellstrom, I and Lieber, A (2006). Effect of adenovirus-mediated heat shock protein expression and oncolysis in combination with low-dose cyclophosphamide treatment on antitumor immune responses. Cancer Res 66: 960-969.
23. Ikeda, K, Ichikawa, T, Wakimoto, H, Silver, JS, Deisboeck, TS, Finkelstein, D et al. (1999). Oncolytic virus therapy of multiple tumors in the brain requires suppression of innate and elicited antiviral responses. Nat Med 5: 881-887.
24. Ikeda, K, Wakimoto, H, Ichikawa, T, Jhung, S, Hochberg, FH, Louis, DN et al. (2000). Complement depletion facilitates the infection of multiple brain tumors by an intravascular, replication-conditional herpes simplex virus mutant. J Virol 74: 4765-4775.
25. Kambara, H, Saeki, Y and Chiocca, EA (2005). Cyclophosphamide allows for in vivo dose reduction of a potent oncolytic virus. Cancer Res 65: 11255-11258.
26. Smakman, N, van der Bilt, JD, van den Wollenberg, DJ, Hoeben, RC, Borel Rinkes, I and Kranenburg, O (2006). Immunosuppression promotes reovirus therapy of colorectal liver metastases. Cancer Gene Ther 13: 815-818.
27. Doronin, K, Toth, K, Kuppuswamy, M, Krajcsi, P, Tollefson, AE and Wold, WSM (2003). Overexpression of the ADP (E3-11.6K) protein increases cell lysis and spread of adenovirus. Virology 305: 378-387.
28. Tollefson, AE, Scaria, A, Hermiston, TW, Ryerse, JS, Wold, LJ and Wold, WSM (1996). The adenovirus death protein (E3-11.6K) is required at very late stages of infection for efficient cell lysis and release of adenovirus from infected cells. J Virol 70: 2296-2306.
29. Tollefson, AE, Ryerse, JS, Scaria, A, Hermiston, TW and Wold, WSM (1996). The E3-11.6kDa Adenovirus Death Protein (ADP) is required for efficient cell death: Characterization of cells infected with adp mutants. Virology 220: 152-162.
30. Ikezawa, Y, Nakazawa, M, Tamura, C, Takahashi, K, Minami, M and Ikezawa, Z (2005). Cyclophosphamide decreases the number, percentage and the function of CD25+ CD4+ regulatory T cells, which suppress induction of contact hypersensitivity. J Dermatol Sci 39: 105-112.
31. Sauthoff, H, Hu, J, Maca, C, Goldman, M, Heitner, S, Yee, H et al. (2003). Intratumoral spread of wild-type adenovirus is limited after local injection of human xenograft tumors: Virus persists and spreads systemically at late time points. Hum Gene Ther 14: 425-433.
32. Harrison, D, Sauthoff, H, Heitner, S, Jagirdar, J, Rom, WN and Hay, JG (2001). Wild-type adenovirus decreases tumor xenograft growth, but despite viral persistence complete tumor responses are rarely achieved - deletion of the viral Elb-19-kD gene increases the viral oncolytic effect. Hum Gene Ther 12: 1323-1332.
33. Heemskerk, B, Lankester, AC, van Vreeswijk, T, Beersma, MF, Claas, EC, Veltrop-Duits, LA et al. (2005). Immune reconstitution and clearance of human adenovirus viremia in pediatric stem-cell recipients. J Infect Dis 191: 520-530.
34. Kampmann, B, Cubitt, D, Walls, T, Naik, P, Depala, M, Samarasinghe, S et al. (2005). Improved outcome for children with disseminated adenoviral infection following allogeneic stem cell transplantation. Br J Haematol 130: 595-603.
35. Watzinger, F, Suda, M, Preuner, S, Baumgartinger, R, Ebner, K, Baskova, L et al. (2004). Real-time quantitative PCR assays for detection and monitoring of pathogenic human viruses in immunobsuppressed pediatric patients. J Clin Microbiol 42: 5189-5198.
36. van Tol, MJ, Claas, EC, Heemskerk, B, Veltrop-Duits, LA, de Brouwer, CS, van Vreeswijk, T et al. (2005). Adenovirus infection in children after allogeneic stem cell transplantation: Diagnosis, treatment and immunity. Bone Marrow Transplant 35 (suppl. 1): S73-576.
37. Lichtenstein, DL, Toth, K, Doronin, K, Tollefson, AE and Wold, WSM (2004). Functions and mechanisms of action of the adenovinus E3 proteins. Int Rev Immunol 23: 75-111.
38. Blandford, G and Charlton, D (1977). Studies of pulmonary and renal immunopathology after nonlethal primary sendai viral infection in normal and cyclophosphamide-treated hamsters. Am Rev Respir Dis 115 305-314.
39. Kercher, L and Mitchell, BM (2000). Immune transfer protects severely immunosuppressed mice from murine cytomegalovirus retinitis and reduces the viral load in ocular tissue. J Infect Dis 182: 652-661.
40. Mitchell, BM and Stevens, JG (1996). Neuroinvasive properties of herpes simplex virus type 1 glycoprotein variants are controlled by the immune response. J Immunol 156: 246-255.
41. Thomas, MA, Spencer, JF and Wold, WSM (2006). Use of the Syrian hamster as an animal model for oncolytic adenovirus vectors. In: Tollefson, AE and Wold, WSM (eds.). Adenovirus Methods and Protocols, 2nd edn. Humana: St. Louis. pp. 169-183.
42. Aste-Amezaga, M, Bett, AJ, Wang, F, Casimiro, DR, Antonello, JM, Patel, DK et al. (2004). Quantitative adenovirus neutralization assays based on the secreted alkaline phosphatase reporter gene: Application in epidemiologic studies and in the design of adenovector vaccines. Hum Gene Ther 15: 293-304.
43. Zhi, Y, Figueredo, J, Kobinger, GP, Hagan, H, Calcedo, R, Miller, JR et al. (2006). Efficacy of severe acute respiratory syndrome vaccine based on a nonhuman primate adenovirus in the presence of immunity against human adenovirus. Hum Gene Ther 17: 500-506.